In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
BUSINESS
Shionogi Commences New COVID Vaccine Trials for Children
Shionogi said on January 17 that it has launched the second part of its two-part PI/II/III trial and a new PIII booster study for its COVID-19 vaccine S-268019, both targeting Japanese children aged five through 11. The jab is currently…
To read the full story
Related Article
- Shionogi Launches 4th-Dose COVID Jab Trial for Ages 60-Plus
July 27, 2022
- Shionogi Begins COVID-19 Vaccine Trial in Children Aged 5-11
July 20, 2022
- Shionogi’s COVID-19 Vaccine Enters PII/III with Japanese Adolescents
May 17, 2022
- Large-Scale Japan Trial for Shionogi Jab Confirms No Major Safety Concerns, Increase in Antibody Titers
April 25, 2022
- Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- Shionogi’s COVID-19 Vaccine Enters Japan PIII, AstraZeneca Jab as Control
January 18, 2022
- Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
- Shionogi’s COVID-19 Vaccine Safe and Tolerable, Increases Antibody Titers: Japan PI/II
December 8, 2021
- Shionogi Kicks Off COVID-19 Booster Trial in Japan
December 6, 2021
- Shionogi Launches Japan PII/III for COVID-19 Vaccine
October 22, 2021
- All 60 Subjects Given 1st Dose of Shionogi COVID-19 Jabs in Japan PI/PII
August 25, 2021
- Shionogi Kicks Off Japan PI/PII Study of COVID-19 Vaccine Candidate
December 17, 2020
BUSINESS
- FDA Approves Izervay’s Wider Label with No Dosing Duration Limit
February 14, 2025
- Susmed to Get 100 Million Yen Milestone after PMS App Trial Start
February 13, 2025
- Regeneron to Upsize Japan Workforce after Libtayo Transfer
February 13, 2025
- Meiji Logs Operating Loss in Vaccine Biz on Kostaive Devaluation
February 12, 2025
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…